|
|
Welcome to
the ISOPP Website
Thanks to our Sponsors
BBC news: WHO has carried out an analysis of the "social determinants" of health
By: Felice Musicco
on: Sat 06 of Sep, 2008 [13:42 UTC]
(5 reads)
|
|
"The World Health Organization (WHO) has carried out a three-year analysis of the "social determinants" of health.
Social factors - rather than genetics - are to blame for huge variations in ill health and life expectancy around the world, a report concludes. "
|
July 2008 Cancer Research Summaries by ESO
By: Felice Musicco
on: Thu 04 of Sep, 2008 [13:29 UTC]
(11 reads)
|
|
Intervention delievered by nurses can help combat depression in cancer patients. 21/07/08
Device can read genetic signature of circulating tumour cells to guide therapy. 14/07/08
Seven biomarkers help predict recurrence in prostate cancer. 07/07/08
|
Alternative Vaccine Strategy Shows Promise in Prostate Cancer Patients
By: Felice Musicco
on: Mon 01 of Sep, 2008 [13:17 UTC]
(15 reads)
|
|
New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the August 15, 2008, issue of Clinical Cancer Research.
|
Identification of ALK as a major familial neuroblastoma predisposition gene
By: Felice Musicco
on: Sat 30 of Aug, 2008 [11:30 UTC]
(30 reads)
|
|
Article in Nature advance online publication 24 August 2008.
Authors Conclusions: "Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal paediatric malignancy."
News received by Rolando Moroni
|
Cochrane review: Computerized advice on drug dosage
By: Felice Musicco
on: Wed 27 of Aug, 2008 [14:29 UTC]
(46 reads)
|
|
Conclusion changed in "Computerized advice on drug dosage to improve prescribing practice" Cochrane Database of Systematic Reviews, Issue 3, 2008.
|
EMEA update on progressive multifocal leukoencephalopathy (PML) and Tysabri
By: Felice Musicco
on: Sat 23 of Aug, 2008 [11:23 UTC]
(47 reads)
|
|
The risk of PML with Tysabri is known and is kept under close monitoring by the EMEA. The product information advises healthcare professionals that the medicine must not be used in patients who have PML and that patients taking Tysabri should be regularly monitored for signs and symptoms suggestive of PML.
|
NICE technology appraisal guidance: Cetuximab for ASCC of the head and neck
By: Felice Musicco
on: Tue 19 of Aug, 2008 [06:56 UTC]
(71 reads)
|
|
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck. "The Committee concluded that cetuximab in combination with radiotherapy is clinically and cost effective in patients with locally advanced squamous cell cancer of the head and neck who have a Karnofsky performance-status score of 90% or greater and for whom platinum-based chemoradiotherapy treatment is contraindicated."
|
FDA List of Approved Oncology Drugs with Approved Indications
By: Felice Musicco
on: Thu 14 of Aug, 2008 [14:54 UTC]
(107 reads)
|
|
The list may be sorted by the drug's generic name, trade name, or manufacturer. Entries also link to an approval summary, a product label, and a sponsor portfolio.
(Note: the data are still incomplete).
|
NEW SIGN Guideline: Antibiotic prophylaxis in surgery
By: Felice Musicco
on: Tue 12 of Aug, 2008 [14:43 UTC]
(110 reads)
|
|
This guideline makes recommendations on best practice in the use of peri-operative prophylactic antibiotics to prevent surgical site infections (SSI). SSI is a major cause of healthcare acquired infection.
The Scottish Intercollegiate Guidelines Network (SIGN) was formed in 1993. Their objective is to improve the quality of health care for patients in Scotland by reducing variation in practice and outcome, through the development and dissemination of national clinical guidelines containing recommendations for effective practice based on current evidence.
|
July's Drug Safety Update by CKS: biphosphonates and atrial fibrillation
By: Felice Musicco
on: Sat 09 of Aug, 2008 [14:35 UTC]
(101 reads)
|
|
The monthly newsletter from the Medicines and Healthcare products Regulatory Agency and its independent advisor the Commission on Human Medicines.
"Clinical trial results have suggested an increased risk of atrial fibrillation for
zoledronic acid (Aclasta), pamidronic acid, and possibly for alendronic acid.
The balance of risks and benefits for bisphosphonates remains favourable"
|
|
ISOPP HOPA 2008
Click on the Logo above to link to the ISOPP/HOPA
symposium page
|
